COMPANY

NephroDi Therapeutics

HQ: Seattle, WA source · nephrodi.com ↗ · West Coast

Keywords: renal nephrogenic diabetes insipidus

Location: Seattle, WA · source · Jun 18, 2024

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $999K (SBIR Phase II 5R44DK127798-03, continuation, notice Jul 27, 2026). NIH RePORTER 5R44DK127798-03 (Jul 27, 2026)
Evidence (1 event)
- Jul 27, 2026 · NIH RePORTER 5R44DK127798-03
  Organization: NEPHRODI THERAPEUTICS, INC.; City/State: Seattle, WA; Project number: 5R44DK127798-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-27; FY total cost (award amount): 998617; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel AMPK activator for treatment of congenital X-linked nephrogenic diabetes insipidus in pediatric patients; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jul 27, 2026 Grant Government grant — SBIR: $998,617 (annual award, as published), announced Jul 27, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Aug 28, 2025 Grant Government grant — SBIR: $1.1M (annual award, as published), announced Aug 28, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Last 2 years.

Jul 27, 2026 Government grant — SBIR: $998,617 (annual award, as published), announced Jul 27, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Aug 28, 2025 Government grant — SBIR: $1.1M (annual award, as published), announced Aug 28, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Annual award amounts. Total $298K.

Sep 11, 2020 NIH award 1R41DK127798-01 FY2020: $297,609 awarded for that fiscal year; activity R41 (STTR); PI SANDS, JEFF M; recipient as written: NEPHRODI THERAPEUTICS, INC., Seattle, WA. Novel AMPK Activators for the Treatment source ↗